ClinicalTrials.gg
CompletedNCT03964831Updated Sep 19, 2024

Study Comparing the P200TxE and P200DTx

An interventional study of P200TxE and P200DTx in Retinal Disease, sponsored by Optos, PLC. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Optos, PLC · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was Jan 2020, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Retinal Diseases with a site in United States — 25 open to participants now, 41 under way, 5 of them phase 3. Retinal Diseases · United States.

Enrollment
53rd of 111
40 · median 36
Started
2019
with 15 others
No phase
27 of 162
6 open now
Registered
89th of 162
by date
Lead sponsor
7 of 162
Optos, PLC

Among the 162 studies in Retinal Diseases with a site in United States, this one is the 53rd largest by enrollment of the 111 interventional ones that give a count, is one of 16 that started in 2019, is one of 27 with no phase, and was the 89th registered.

Retinal Diseases

333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.

Browse Retinal Diseases studies →

Open to participants now

25 of the 162 studies in Retinal Diseases with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Retinal Diseases with a site in United States, or all of them as a file.
02

Study summary

The study evaluates image quality between two devices.

03

Conditions studied

  • Retinal Disease

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the is signed;
  2. Subjects who can follow the instructions by the clinical staff at the clinical site,
  3. Subjects who agree to participate in the study;
  4. Subjects diagnosed with retinal pathology. Example of pathologies may include but are not limited to Age-related Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy, and others as confirmed by the investigator;

Exclusion criteria

Exclusion Criteria:

  1. Subjects unable to tolerate ophthalmic imaging;
  2. Subjects with ocular media not sufficiently clear to obtain acceptable images;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Other
    Ultra widefield image capture

    Device: P200TxE · Device: P200DTx

Interventions

  • DeviceP200TxE

    The P200TxE ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.

  • DeviceP200DTx

    The P200DTx ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.

06

What researchers measure

Primary outcomes

  1. Qualitative Image assessment

    Results from a qualitative assessment of the clinical utility and image quality of the images from both devices will be assessed from a clinician questionnaire and three independent masked and qualified graders using a four point scale (0-3).

    Time frame: 6 months

  2. Safety Assessment from Adverse Events

    Analysis of safety will be assessed through adverse events reported by the site and documented on each subject's case report form.

    Time frame: 6 months

07

Study locations

1 site
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jan 2020, 6 months.

Of 42 interventional studies with no phase under Retinal Diseases, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 66. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2019
First posted
May 28, 2019
StartActual
Jun 18, 2019
Primary completionActual
Jan 14, 2020
CompletionActual
Jan 14, 2020
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03964831
Lead sponsor
Optos, PLC
Responsible party
Sponsor
First posted
May 28, 2019
Start date
Jun 18, 2019
Primary completion
Jan 14, 2020
Completion
Jan 14, 2020
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion